Outcomes of Left Ventricular Assist Device Implantation in Patients With Uncommon Etiology Cardiomyopathy - Université de Rennes Accéder directement au contenu
Article Dans Une Revue American Journal of Cardiology Année : 2020

Outcomes of Left Ventricular Assist Device Implantation in Patients With Uncommon Etiology Cardiomyopathy

1 LTSI - Laboratoire Traitement du Signal et de l'Image
2 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
3 Service de chirurgie thoracique cardiaque et vasculaire [Rennes] = Thoracic and Cardiovascular Surgery [Rennes]
4 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
5 Service Cardiologie [CHU Toulouse]
6 IHU-LIRYC
7 CRCTB - Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux]
8 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
9 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
10 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
11 Service de chirurgie thoracique et cardio-vasculaire
12 CHU Nantes - Centre Hospitalier Universitaire de Nantes
13 CIC - Grenoble
14 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
15 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
16 TIMONE - Hôpital de la Timone [CHU - APHM]
17 C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
18 Département de Cardiologie [Hôpital de la Timone - APHM]
19 CMU - Carnegie Mellon University [Pittsburgh]
20 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
21 Service de Cardiologie [CHU Rouen]
22 CHU Caen
23 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
24 Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes]
25 CHU Henri Mondor [Créteil]
26 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
27 CHU Clermont-Ferrand
28 chirurgie cardio-vasculaire
29 HEGP - Hôpital Européen Georges Pompidou [APHP]
30 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
31 Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]
Clément Delmas
François Picard
  • Fonction : Auteur
  • PersonId : 782777
  • IdRef : 16055652X
Aude Boignard
  • Fonction : Auteur
Frédéric Anselme
Gerard Babatasi
  • Fonction : Auteur
Katrien Blanchart
  • Fonction : Auteur
Nicolas Lellouche
  • Fonction : Auteur
  • PersonId : 764872
  • IdRef : 075154625
Thibaud Genet
Romain Eschalier
Nicolas d'Ostrevy
  • Fonction : Auteur
  • PersonId : 1345629
  • IdHAL : ndostrevy

Résumé

The impact of uncommon etiology cardiomyopathies on Left-ventricular assist device (LVAD)-recipient outcomes is not very well known. This study aimed to characterize patients with uncommon cardiomyopathy etiologies and examine the outcomes between uncommon and ischemic/idiopathic dilated cardiomyopathy. This observational study was conducted in 19 centers between 2006 and 2016. Baseline characteristics and outcomes of patients with uncommon etiology were compared to patients with idiopathic dilated/ischemic cardiomyopathies. Among 652 LVAD-recipients included, a total of 590 (90.5%) patients were classified as ischemic/idiopathic and 62 (9.5%) patients were classified in the "uncommon etiologies" group. Main uncommon etiologies were: hypertrophic (n = 12(19%)); cancer therapeutics-related cardiac dysfunction (CTRCD) (n = 12(19%)); myocarditis (n = 11(18%)); valvulopathy (n = 9(15%)) and others (n = 18(29%)). Patients with uncommon etiologies were significantly younger with more female and presented less co-morbidities. Additionally, patients with uncommon cardiomyopathies were less implanted as destination therapy compared with ischemic/idiopathic group (29% vs 38.8%). During a follow-up period of 9.1 months, both groups experienced similar survival. However, subgroup of hypertrophic/valvular cardiomyopathies and CTRCD had significantly higher mortality compared to the ischemic/idiopathic or myocarditis/others cardiomyopathies. Conversely, patients with myocarditis/others etiologies experienced a better survival. Indeed, the 12-months survival in the myocarditis/others; ischemic/idiopathic and hypertrophic/CTRCD/valvulopathy group were 77%; 65%, and 46% respectively. In conclusion, LVAD-recipients with hypertrophic cardiomyopathy, valvular heart disease and CTRCD experienced the higher mortality rate.
Fichier principal
Vignette du fichier
Galand et al-2020-Outcomes of Left Ventricular Assist Device Implantation in Patients with.pdf (723 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02502716 , version 1 (22-06-2020)

Identifiants

Citer

Vincent Galand, Erwan Flécher, Céline Chabanne, Bernard Lelong, Céline Goéminne, et al.. Outcomes of Left Ventricular Assist Device Implantation in Patients With Uncommon Etiology Cardiomyopathy. American Journal of Cardiology, 2020, 125 (9), pp.1421-1428. ⟨10.1016/j.amjcard.2020.01.042⟩. ⟨hal-02502716⟩
160 Consultations
300 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More